Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 12/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148813 | 0.92 | RPA1 (0.47) | RPA1SMOMALT1CACNA1GCACNA1H | |
| SCHEMBL5148847 | 0.88 | RPA1 (0.55) | RPA1MALT1CACNA1GCACNA1HCHRNA7 | |
| Hydrochloric Acid SCHEMBL5151848 | 0.88 | MALT1 (0.43) | RPA1SMOMALT1CHRNA7NFKB1 | |
| SCHEMBL5148755 | 0.87 | MDM2 (0.40) | RPA1MALT1CHRNA7NFKB1NFKB2 | |
| SCHEMBL5148772 | 0.87 | RPA1 (0.42) | RPA1SMOMALT1CHRNA7 | |
| SCHEMBL14504508 | 0.87 | MALT1 (0.42) | RPA1SMOMALT1CHRNA7NFKB1 | |
| SCHEMBL14504623 | 0.86 | MALT1 (0.43) | RPA1SMOMALT1CHRNA7NFKB1 | |
| SCHEMBL5152187 | 0.85 | RPA1 (0.44) | RPA1SMOMALT1CACNA1GCACNA1H | |
| SCHEMBL14504534 | 0.84 | MALT1 (0.39) | RPA1SMOMALT1CHRNA7NFKB1 | |
| SCHEMBL5532092 | 0.83 | MALT1 (0.41) | RPA1MALT1CHRNA7NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567503-B1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1567503-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20040116475-A1 | Pyrazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2004050632-A1 | PYRAZOLE DERIVATIVES USEFUL AS COX-I INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | RPA1 2143/4885SMO 3090/4885MALT1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.